CLINICAL & PIPELINE·Drug Approval
TEVA PHARMS USA Gains FDA Approval for Generic EFINACONAZOLE 10% Topical Solution, Reshaping Antifungal Market Dynamics
TEVA PHARMS USA has secured FDA approval for its generic EFINACONAZOLE 10% topical solution (ANDA211827) on December 16, 2020. This approval introduces a therapeutically equivalent alternative, intensifying competition in the antifungal market. Procurement directors should evaluate TEVA as a new supplier, while supply chain VPs must anticipate potential price erosion and adjust sourcing strategies for this key molecule.
90-Day Activity